Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7772
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy ; day:26 ; month:5 ; year:2017 ; pages:1-8
International journal of clinical oncology ; (26.5.2017), 1-8
- Schlagwort
-
Biopharmazie
Pharmakodynamik
Pharmakokinetik
- Urheber
-
Shiseki, Masayuki
- Beteiligte Personen und Organisationen
-
Yoshida, Chikashi
Takezako, Naoki
Ohwada, Akira
Kumagai, Takashi
Nishiwaki, Kaichi
Horikoshi, Akira
Fukuda, Tetsuya
Takano, Hina
Kouzai, Yasuji
Tanaka, Junji
Morita, Satoshi
Sakamoto, Junichi
Sakamaki, Hisashi
Inokuchi, Koiti
SpringerLink (Online service)
- DOI
-
10.1007/s10147-017-1141-y
- URN
-
urn:nbn:de:1111-201706105835
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shiseki, Masayuki
- Yoshida, Chikashi
- Takezako, Naoki
- Ohwada, Akira
- Kumagai, Takashi
- Nishiwaki, Kaichi
- Horikoshi, Akira
- Fukuda, Tetsuya
- Takano, Hina
- Kouzai, Yasuji
- Tanaka, Junji
- Morita, Satoshi
- Sakamoto, Junichi
- Sakamaki, Hisashi
- Inokuchi, Koiti
- SpringerLink (Online service)
Ähnliche Objekte (12)
A Case Report of BCR-ABL-JAK2-Positive Chronic Myeloid Leukemia with Complete Hematological and Major Molecular Response to Dasatinib
Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia
Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia
Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
The Role of Early Molecular Response in the Management of Chronic Phase CML
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
Successful Dasatinib Treatment of Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma and BCR-ABL1 -Positive Chronic Myeloid Leukemia: A Case Report
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy
A Case Report of BCR-ABL-JAK2-Positive Chronic Myeloid Leukemia with Complete Hematological and Major Molecular Response to Dasatinib
Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia
Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia
Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
The Role of Early Molecular Response in the Management of Chronic Phase CML
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
Successful Dasatinib Treatment of Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma and BCR-ABL1 -Positive Chronic Myeloid Leukemia: A Case Report
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy
A Case Report of BCR-ABL-JAK2-Positive Chronic Myeloid Leukemia with Complete Hematological and Major Molecular Response to Dasatinib
Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia
Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia
Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
The Role of Early Molecular Response in the Management of Chronic Phase CML
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
Successful Dasatinib Treatment of Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma and BCR-ABL1 -Positive Chronic Myeloid Leukemia: A Case Report
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV